Is human papilloma virus vaccination effective for oral cancer?

as a qHPV vaccine and Cervarix (Glaxo-SmithKline, Middlesex, UK) as a bivalent HPV (biHPV) vaccine. Both of these vaccines are effective for HPV subtypes 16 and 18, and Gardasil is effective against the two additional subtypes 6 and 11. The biHPV vaccine was approved for development in 1998, received FDA approval in 2009, and is now licensed in more than 100 countries and approved in more than 60 other countries. The qHPV vaccine, also called the Merck vaccine, was developed early and has the same structure as HPV 16, which was used as a main constituent in 1993, and was approved by the FDA in 2006. The side effects of HPV vaccination are regional pain, swelling, redness, urticaria, fever, dysphagia, and muscular pain, but most of these local or general responses resolve within several days. More recently, the Korean Food and Drug Administration (KFDA) approved the efficacy of two imported vaccination drugs for the prevention of anal, vulvar, and vaginal cancers when it is appropriately inoculated in young women before their first sexual experience. Oropharyngeal cancer can be broadly defined to include the oral cavity, pharynx, tonsils, and some parts of the deep pha-ryngeal wall. However, a more strictly differentiated meaning of the oropharynx is the posterior part of the oral cavity including the base of the tongue, tonsils, and pharyngeal wall. This pharyngeal mucosa composed of the reticulated epitheli-um and some crypts of the tonsils provides a kind of immune system that is vulnerable to HPV invasion with subsequent virion penetration. With inclusion of HPV infection in the laryngeal region, this HPV-prevalent region was considered head and neck cancer by previous clinicians and pathologists. Based on this previous information and knowledge, we must concentrate on pure oral cancer of the oral cavity including gingival, buccal mucosa, tongue, palate, and lip cancers for future prevention of HPV infection through large-scale HPV inoculations in females. This indicates that there will be fewer female oral cancer patients in the next 20 to 30 On June 20, 2016, the Korean Center for Disease Control and Prevention (KCDC) began offering free human papil-loma virus (HPV) vaccination as part of the Korean National Immunization Program. According to an official publication of the Division of Vaccine Preventable Diseases Control & the National Immunization Program of the KCDC, this HPV vaccination will be offered for 12-year-old girls and is expected to prevent cer-vical, anogenital, anal, and even …